Brandon Malone

Title: Brandon Malone: Innovator in Neoantigen-Based Immunotherapy

Introduction

Brandon Malone is a notable inventor based in Dossenheim, Germany. He has made significant contributions to the field of immunotherapy, particularly in the development of personalized cancer treatments. His innovative approach focuses on targeting neoantigens to enhance immune responses in cancer patients.

Latest Patents

Brandon Malone holds a patent for a method and system of targeting epitopes for neoantigen-based immunotherapy. This patent outlines a method of ranking epitopes derived from neoantigens as targets for personalized immunotherapy. The process involves collecting candidate epitopes based on patient data and calculating a set of scores for each candidate. These scores represent the likelihood of each epitope to elicit an immune response in the cancer patient. The scores are then combined into a single score for each candidate epitope, reflecting the overall likelihood of eliciting an immune response. This innovative method aims to improve the effectiveness of immunotherapy for cancer patients.

Career Highlights

Brandon Malone is currently associated with Nec Corporation, where he continues to work on advancements in immunotherapy. His expertise and innovative mindset have positioned him as a key player in the field of cancer treatment.

Collaborations

Brandon collaborates with talented individuals such as Kousuke Onoue and Yoshiko Yoshihara. Their combined efforts contribute to the ongoing research and development in the area of neoantigen-based therapies.

Conclusion

Brandon Malone's work in neoantigen-based immunotherapy represents a significant advancement in personalized cancer treatment. His innovative methods and dedication to improving patient outcomes highlight the importance of targeted therapies in modern medicine.